



Conditions	Indications	Study	Treatment/MOA	NIH website	Who Qualifies	
Alzheimer's Memory	Memory Loss	TRAVELLER	pTau217 Blood Biomarker (Diagnostic only, NO Treatment)		Memory Loss	
	MCI, AD	ALZ NET	Nationally Designated HI AD Registry Site 6239	ALZ NET US Sites	On mAb Treatments	
	MCI, Mild AD	TRONTIER	IV Trontinemab (mAb BrainShuttle Technology)	NCT04639050	MMSE 22-30	
	MCI, Mild AD	TREM 2	IV VHB937 (mAb ↓ Neuroinflammation)	NCT07094516	CDR 0.5-1	
	MCI, Mild AD		PO Buntanetap (↓ Neuroinflammation)	NCT06709014	MMSE 21-28	
Parkinson's Movement Dis	AD, Agitation	BALANCE	PO BMS-986368	NCT06808984	MMSE < 21, NPI-NH > 4	
	Early Parkinson's	PARAISO	IV Prasinezumab (α-Synuclein binding mAb)	NCT07174310	UPDRS 0 H & Y Stage 1 or 2	
	Lewy Body/PD Dementia	Psychosis	PO Remlifanserin (5HT2A Agonist)	NCT07029581	PD or DLB & Psychosis	
	Focal Seizure	RISE 2	PO BHV-7000 VG Potassium channel	NCT06132893	> 4 seizures/month	
	Focal Seizure	X-TOLE2	PO XEN1101 Novel Potassium channel	NCT05614063	> 4 seizures/month	
Epilepsy	Primary Generalized	X-TOLE3	PO XEN1101 Novel Potassium channel	NCT05667142	3 PGTC in 8 weeks	
	Focal or Generalized	STARS	Inhaled Abortive EP0162 Staccato Alprazolam	NCT05077904	Seizures	
	Neuroimmunology	MS Implementation Network (MSIN)	Nationally Designated HI MS Registry site	MSSA MSIN website	MS Living in HI	
		RRMS		IV ABP 692 vs Ocrevus	NCT06700343	≥ 2 relapse EDSS ≤ 5.5
		SPMS	REMASTER	Remibrutinib		SPMS, EDSS 3-6
SPMS or PPMS	MINTAKA	Oral RO7268489 Monoacylglycerol Lipase Inh		PPMS < 10 yr, EDSS 3-6		
Neuromuscular			Add on Therapy to OCRELIZUMAB		SPMS < 20 yr, EDSS 3-6	
	CIDP	HYBISCUE	SC HyQvia	NCT06538064	CIDP 2021 Guidelines	
	gMyasthenia Gravis	ADAPT-EARLY	SC Efgartigimod PH20	NCT06909214	Generalized MG	
	CIDP	CAPTIVATE	SC DNTH103	NCT06858579	CIDP CDAS > 3	
	Motor Neuropathy	MOMENTUM	IV DNTH103	NCT06537999	Multifocal Motor Neuropathy	
Headache/Pain	Migraine Menstrual	MOSAIC	PO Ubrogepant	NCT06417775	Migraine > 12 months	
	Migraine Episodic	MINT-E	SC Xeomin	NCT07018700	6-14 migraine/mth	
	Migraine Chronic	MINT-C	SC Xeomin	NCT07018713	≥ 8 migraine/mth	
	Psychiatric Neuro	Dépression Post Partum	RECONNECT	SC RE 104	NCT06342310	DSM5 Post PD
Adjustment Disorder		ADCO	SC RE 104	NCT07002034	AjD > 4 weeks	
ALS, MS, Parkinson's						
Rare Neuro Diseases	Psychosis in DLB or PD		PO Remlifanserin (5HT2A Agonist)	NCT07029581	PD or DLB & Psychosis	
	Dentatorubral-Pallidoluysian Atrophy	Intrathecal nL-ATN-002		FDA IND 173123	Open label single center single patient	